All data are based on the daily closing price as of December 23, 2024
a
Astellas Pharma
4503.TSE
9.70 USD
-0.15
-1.52%
Overview
Last close
9.70 usd
Market cap
17.36B usd
52 week high
14.96 usd
52 week low
9.35 usd
Target price
12.68 usd
Valuation
P/E
50.5075
Forward P/E
12.3457
Price/Sales
1.5281
Price/Book Value
1.8047
Enterprise Value
21.45B usd
EV/Revenue
1.8955
EV/EBITDA
12.4336
Key financials
Revenue TTM
11.32B usd
Gross Profit TTM
6.66B usd
EBITDA TTM
2.34B usd
Earnings per Share
0.2 usd
Dividend
0.68 usd
Total assets
24.29B usd
Net debt
4.45B usd
About
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.